title: PET/computed tomography and lymphoma.
abstract: [¹⁸F]Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scans provide patients and referring physicians with diagnostic PET and CT information in a single imaging session. Because most lymphomas show high glucose metabolic activity and FDG avidity, they can be reliably assessed with FDG-PET/CT. PET/CT has emerged as the modality of choice for treatment strategy assessments in patients with lymphoma. Its ability to characterize masses as benign or malignant and its high sensitivity and specificity for staging, restaging, and treatment monitoring have led to widespread acceptance of PET imaging for managing patients with lymphoma.
authors.affiliation: Ahmanson Translational Imaging Division/Nuclear Medicine, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-6948, USA. Electronic address: mauerbach@mednet.ucla.edu.
authors.forename: Martin
authors.initials: M
authors.lastname: Allen-Auerbach
authors.forename: Sven
authors.initials: S
authors.lastname: de Vos
authors.forename: Johannes
authors.initials: J
authors.lastname: Czernin
mesh_terms: D016477:Artifacts; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology; D064847:Multimodal Imaging; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000473:pathology; D009367:Neoplasm Staging; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: FDG; Lymphoma; PET; PET/CT